Products
Danburstotug Biosimilar Antibody Fusion Protein (PD-L1) for Research
Cat No.: GMP-Bios-INN-1150
Anti-PDL1/CD274 therapeutic antibody (Pre-made Danburstotug biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Danburstotug (development code IMC-001) is an antibody fusion protein targeting PD-L1 (CD274). It is developed by Sorrento Therapeutics, Asan Medical Center and ImmuneOncia Therapeutics for extranodal NK-T-cell lymphoma, gastric cancer, liver cancer among others. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1150-1mg | 1mg | 3090 |
| GMP-Bios-INN-1150-10mg | 10mg | |
| GMP-Bios-INN-1150-100mg | 100mg | |
| GMP-Bios-INN-1150-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Danburstotug biosimilar, Whole mAb Fusion, Anti-PDL1/CD274 Antibody: Anti-PD-L1/CD274/Programmed cell death 1 ligand 1/PDCD1 ligand 1 therapeutic antibody |
| INN Name | Danburstotug |
| Target | PDL1/CD274 |
| Format | Whole mAb Fusion |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Sorrento Therapeutics;Asan Medical Center;ImmuneOncia Therapeutics |
| Conditions Approved | na |
| Conditions Active | Extranodal NK-T-cell lymphoma;Gastric cancer;Liver cancer;Oesophageal cancer;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
